<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790413</url>
  </required_header>
  <id_info>
    <org_study_id>385/2005</org_study_id>
    <nct_id>NCT00790413</nct_id>
  </id_info>
  <brief_title>Haploidentical Stem Cell Transplantation in Neuroblastoma</brief_title>
  <official_title>High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University Hospital</source>
  <brief_summary>
    <textblock>
      Children with primary resistant or relapsed neuroblastoma who do not achieve remission with
      conventional chemotherapy have extremely dismal prognosis. A novel treatment strategy
      combining tumor targeted radioisotope treatment with metaiodobenzylguanidine (MIBG) and
      immunotherapeutic effect of haploidentical stem cell transplantation (haploSCT) followed by
      low-dose donor lymphocyte infusions will be piloted. The use of the isotope is aimed to
      decrease pre-transplant tumour burden. Reduced intensity conditioning containing Fludarabine,
      Thiotepa and Melfalan will enable sustained engraftment as well as will serve as additional
      anti-tumor treatment. A prompt natural killer (NK)-cell mediated tumour control may be
      achieved by haploidentical stem cell transplantation. The investigators hypothesize that
      tumour cells potentially evading NK-cell mediated immunity may be targeted by infused donor
      T-cells and eliminated by either MHC-dependent manner or through a bystander effect. The
      possible graft versus tumor effect will be evaluated in children with therapy resistant
      neuroblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2005</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological reconstitution</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft versus host disease</measure>
    <time_frame>day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iodine I 131 metaiodobenzylguanidine</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>T-cell depletion</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haploidentical stem cell transplantation</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Donor Lymphocyte Infusion</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Co-transplantation of mesenchymal stem cells</intervention_name>
    <arm_group_label>High-dose MIBG with haploidentical stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory neuroblastoma (any chemo/radiosensitive stable disease)

          -  Relapse incl. autologous HSCT 3 m earlier

          -  Primary induction failure

          -  Cardiac output SF ≥25%

          -  Creatinine clearance ≥40 cc/min/1.73 m2

          -  Performance score of ≥50% (Lansky or Karnofsky)

          -  Available haploidentical family donor, aged ≥18 yrs, HIV-neg

        Exclusion Criteria:

          -  Rapidly progressive disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Toporski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Department of Pediatric Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Inoue M, Nakano T, Yoneda A, Nishikawa M, Nakayama M, Yumura-Yagi K, Sakata N, Yasui M, Okamura T, Kawa K. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant. 2003 Jul;32(1):103-6.</citation>
    <PMID>12815485</PMID>
  </reference>
  <reference>
    <citation>Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20;24(3):500-6.</citation>
    <PMID>16421427</PMID>
  </reference>
  <reference>
    <citation>Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci. 2004 Dec;1028:69-80. Review.</citation>
    <PMID>15650233</PMID>
  </reference>
  <reference>
    <citation>Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother. 2004 Jan;53(1):41-52. Epub 2003 Sep 18.</citation>
    <PMID>14504825</PMID>
  </reference>
  <reference>
    <citation>Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005 Jul 7;24(29):4634-44.</citation>
    <PMID>15897905</PMID>
  </reference>
  <reference>
    <citation>Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Föll J, Martin D, Handgretinger R. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr. 2006 Nov-Dec;218(6):321-6.</citation>
    <PMID>17080334</PMID>
  </reference>
  <results_reference>
    <citation>Toporski J, Garkavij M, Tennvall J, Ora I, Gleisner KS, Dykes JH, Lenhoff S, Juliusson G, Scheding S, Turkiewicz D, Békássy AN. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant. 2009 Sep;15(9):1077-85. doi: 10.1016/j.bbmt.2009.05.007. Epub 2009 Jul 8.</citation>
    <PMID>19660720</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>March 11, 2017</last_update_submitted>
  <last_update_submitted_qc>March 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University Hospital</investigator_affiliation>
    <investigator_full_name>Jacek Toporski</investigator_full_name>
    <investigator_title>MD, PhD, Head, Section of Pediatric Oncology/Hematology</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

